Theory 9

PDA EU
Freeze – Drying In Practice

Dr. Julian Lenger

Head of Laboratory in Parenteral Drug Development at Bayer AG;

julianh.lenger@gmail.com

24 – 28 October 2022
Martin Christ
Osterode am Harz, Germany

Adapted from slides originally created and kindly provided by PD Dr. Andrea Allmendinger

Controlled nucleation



Low degree of supercooling

↓

Big dentritic ice crystals

↓

Morphology / Product resistance

↓

Drying time

- Increases inter-/intra-batch- and vial-to-vial homogeneity
- Shorter primary drying
- Better stability (?)

Review: Geidobler R, Winter G. Eur J Pharm Biopharm. 2013 Oct;85(2):214-22

Video

Video1_IceFog.wmv

Com1ecting People, Science and Regulation

Monitoring



Uncontrolled ice nucleation



Controlled ice nucleation

Gitter JH, Geidobler R, Presser I, Winter G. A Comparison of Controlled Ice Nucleation Techniques for Freeze-Drying of a Therapeutic Antibody. *J Pharm Sci*. **2018**;107(11):2748–54.

Methods for controlled nucleation



Literature recommendation:

processes

MDPI

Article

Comparison of Techniques to Control Ice Nucleation during Lyophilization

Jacob Luoma [1,†], Erika Ingham [1], Carmen Lema Martinez [2] and Andrea Allmendinger [2,3,*,†]

Roche

Controlled Ice Nucleation during Lyophilization

- Comparison of Nucleation Techniques and their Impact on Protein Stability

Andrea Allmendinger and Jake Luoma

Pharmaceutical Development
Roche/Genentech, Basel/San Francisco

Conference Freeze-Drying of Pharmaceuticals and Biologics
Garmisch-Patenkirchen, September 2018

Reprint of slides originally created and kindly provided by PD Dr. Andrea Allmendinger

Outline

Roche

—

Background to controlling ice nucleation (CIN)

- Benefits
- Technologies

=

Case-study:

Comparison of nucleation techniques

- Solid state
- Stability
- Challenges

≡

Summary and take-home messages

Outline

Roche

—

Background to controlling ice nucleation (CIN)

- Benefits
- Technologies

=

Case-study:

Comparison of nucleation techniques

- Solid state
- Stability
- Challenges

≡

Summary and take-home messages

Standard freezing step



Nucleation temperature impacts cake structure, CQAs, and cycle time



Geidobler et al.: Controlled ice nucleation in the field of freeze drying: Fundamentals and technology review. Eur J Pharm Biopharm. 85(2):214-22. (2013).

Pros of CIN

+ **Increase inter-vial homogeneity**
+ Shorter primary drying
+ Improved cake appearance

Cons of CIN

- Higher residual moisture
- Intra-vial homogeneity
- Additional process step

→ Lower vial-to-vial variability reduces scale differences and improves confidence in technical transfers especially for products which are difficult to lyophilize like molecules which are sensitive to moisture or surface area

Technologies for controlling ice nucleation

- Techniques used in the following case study

Depressurization

SP Scientific ControLyo®



Partial Vacuum

HOF SynchroFreeze™



Ice Fog

Linde/IMA VERISEQ®

Martin Christ LyoCoN,...



Controlled ice nucleation - Modes of operation

Depressurization



Partial Vacuum



Ice Fog



Nucleation event

Outline

Roche

–

Background to controlling ice nucleation (CIN)

- Benefits
- Technologies

=

Case-study:

Comparison of nucleation techniques

- Solid state
- Stability
- Challenges

≡

Summary and take-home messages

Study design & objective

Examining the impact of vial size and formulation

- Determine whether each technology produces comparable drug product when using similar freezing protocols
- Identify any processing limitations under challenging conditions

Formulation #	Type of protein	Protein concentration	Total solid content	Main excipient*	Vial format (cc)	Nominal fill (mL)
1	mAb IgG_1 (148 kDa)	10 mg/mL	9%	240 mM Sucrose	2	1
					20	10
					50	20
2	mAb IgG_1 (148 kDa)	100 mg/mL	18%	240 mM Sucrose	2	1
					20	10
					50	20
3	Enzyme (59 kDa)	2.5 mg/mL	11%	500 mM Arginine Phosphate	6	0.9
					20	10
					50	20

** All formulations contain a formulation buffer and surfactant.*

Nucleation temperatures achieved

Overview of nucleation temperatures for different formulations.

Formulation #	Protein conc.	Total solid content	Vial format (cc)	Nominal fill (mL)	Highest controlled nucleation temperature achieved		
					Depressurization	Partial vacuum	Ice fog
1	10 mg/mL mAb	9%	2	1	Failure to nucleate (UCN)	-5	-5
			20	10	-5	-5	-5
			50	20	-5	-5	-5
2	100 mg/mL mAb	18%	2	1	Failure to nucleate (UCN)	-15	n.p.
			20	10	-5	-15	-5
			50	20	-5	-15	n.p.
3	2.5 mg/mL enzyme	11%	6	0.9	-10	-5	n.p.
			20	10	-5	-5	n.p.
			50	20	-10	-15	-10

n.p. = not performed, UCN = uncontrolled nucleated

- Depressurization method struggled with 2cc vials
- Partial vacuum method struggled with Formulation 2/3 (high total solids)

Nucleation at the same temperature

– solid state characterization

Formulation 1: 10 mg/mL mAb, nucleation temperature: **-5°C**



- Nucleation at the same temperature resulted in comparable solid state properties

Nucleation at the same temperature

– cake appearance

Formulation 1: 10 mg/mL mAb, nucleation temperature: **-5°C** **(10 mL in 20cc vial)**

Partial vacuum	Depressurization	Ice fog	Uncontrolled
			

- Nucleation at the same temperature resulted in comparable visual cake structure. No denting was observed with controlled nucleation.
- There were no significant changes on (accelerated) stability (SEC/IEC 5/25/40°C 1Y)

Nucleation temperatures achieved

Overview of nucleation temperatures for different formulations.

Formulation #	Protein conc.	Total solid content	Vial format (cc)	Nominal fill (mL)	Highest controlled nucleation temperature achieved		
					Depressurization	Partial vacuum	Ice fog
1	10 mg/mL mAb	9%	2	1	Failure to nucleate (UCN)	-5	-5
			20	10	-5	-5	-5
			50	20	-5	-5	-5
2	100 mg/mL mAb	18%	2	1	Failure to nucleate (UCN)	-15	n.p.
			20	10	-5	-15	-5
			50	20	-5	-15	n.p.
3	2.5 mg/mL enzyme	11%	6	0.9	-10	-5	n.p.
			20	10	-5	-5	n.p.
			50	20	-10	-15	-10

n.p. = not performed, UCN = uncontrolled nucleated

- Depressurization method struggled with 2cc vials
- Partial vacuum method struggled with Formulation 2/3 (high total solids)

Nucleation at different temperatures

– solid state characterization

Formulation 2: 100 mg/mL mAb, nucleation temperature: **-5°C** and **-15°C**



- Nucleation ten degrees apart resulted in large changes to solid state properties

Nucleation at different temperatures

– cake appearance and macroscopic cake structure

Formulation 2: 100 mg/mL mAb, nucleation temperature: **-5°C** and **-15°C**



- Nucleation ten degrees apart resulted in large changes in cake structure and macroscopic cake structure

Nucleation at different temperatures

– cake appearance and macroscopic cake structure

Formulation 2: 100 mg/mL mAb, nucleation temperature: **-5°C** and **-15°C**



- Nucleation ten degrees apart resulted in large changes in cake structure and macroscopic cake structure
- Depressurization and Ice fog samples revealed crystal-like patterns but differed to each other

Nucleation at different temperatures

– stress stability (SEC, 40°C)

Formulation 2: 100 mg/mL mAb, nucleation temperature: **-5°C** and **-15°C** (20cc vial)





UCN = uncrontrolled nucleated, r.m. = residual moisture

- Nucleation ten degrees apart resulted in different stability

Nucleation at different temperatures

– stress stability (SEC, 40°C)

Formulation 2: 100 mg/mL mAb, nucleation temperature: **-5°C** and **-15°C** (20cc vial)





UCN = uncrontrolled nucleated, r.m. = residual moisture

- Nucleation ten degrees apart resulted in different stability
- However, residual moisture most important stability-impacting solid state property

Nucleation temperatures achieved

Overview of nucleation temperatures for different formulations.

Formulation #	Protein conc.	Total solid content	Vial format (cc)	Nominal fill (mL)	Highest controlled nucleation temperature achieved		
					Depressurization	Partial vacuum	Ice fog
1	10 mg/mL mAb	9%	2	1	Failure to nucleate (UCN)	-5	-5
			20	10	-5	-5	-5
			50	20	-5	-5	-5
2	100 mg/mL mAb	18%	2	1	Failure to nucleate (UCN)	-15	n.p.
			20	10	-5	-15	-5
			50	20	-5	-15	n.p.
3	2.5 mg/mL enzyme	11%	6	0.9	-10	-5	n.p.
			20	10	-5	-5	n.p.
			50	20	-10	-15	-10

n.p. = not performed, UCN = uncontrolled nucleated

- Depressurization method struggled with 2cc vials
- Partial vacuum method struggled with Formulation 2/3 (high total solids)

Nucleation at different temperatures

– solid state characterization

Formulation 3: 2.5 mg/mL enzyme



n.p. = not performed

					Depressurization	Partial vacuum	Ice fog
3	2.5 mg/mL enzyme	11%	6	0.9	-10	-5	n.p.
			20	10	-5	-5	n.p.
			50	20	-10	-15	-10

n.p. = not performed, UCN = uncontrolled nucleated

- Nucleation five degrees apart resulted in in general comparable residual moisture and small changes to specific surface area

Nucleation at different temperatures

– stress stability (SEC, 45°C & 60°C)

Formulation 3: 2.5 mg/mL enzyme



- Comparable solid state properties but different stability under stress conditions?

Nucleation at different temperatures

– macroscopic cake structure (PDMS Cake Embedding)

Formulation 3: 2.5 mg/mL enzyme, 50cc











- Nucleation five degrees apart resulted in small changes to macroscopic cake structure

Nucleation at different temperatures

– macroscopic cake structure by µCT

Formulation 3: 2.5 mg/mL enzyme, **50cc**

Depressurization -10 °C



Partial Vacuum -15 °C



Ice Fog -10 °C



Ice Fog -15 °C



- Differences in stability potentially due to microcollapse dependent on nucleation technique (enzyme is a surface sensitive molecule)?

Outline

Roche

–

Background to controlling ice nucleation (CIN)

- Benefits
- Technologies

=

Case-study:

Comparison of nucleation techniques

- Solid state
- Stability
- Challenges

≡

Summary and take-home messages

Summary

- Robustness testing for formulation and vial configuration revealed
  - Depressurization method struggled with 2cc vials
  - Partial vacuum method struggled with formulation with very high total solid content



- Nucleation at the same temperature resulted in comparable solid state properties like residual moisture and specific surface area, which directly relates to stability behavior dependent on the molecule studied



- Specific example showed that macroscopic structure (top layer) may be different between nucleation techniques, which may impact drying behavior, and is currently further studied

Take-home message

- Each technology has limitations
  - Depending on vial format and formulation you may need to nucleate at lower temperatures to ensure robust nucleation, which triggers formulation and configuration dependent process development
  - If operating conditions result in microcollapse, comparability between material produced with the different CIN technologies is not guaranteed
- Each technologies has different installation and operation requirements like availability, location and size of ports or availability of liquid nitrogen